Biomea Fusion, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on April 1, 2024, the compensation committee of Biomea's board of directors granted two new employees non-qualified stock options to purchase an aggregate of 6,500 shares of the Company's common stock. The shares underlying each employee's stock options will vest 1/16 on a quarterly basis over four years, in each case subject to each such employee's continued employment with the Company on such vesting dates. All of the above-described awards were made under Biomea's 2023 Inducement Equity Plan (the "Plan").
加利福尼亚州雷德伍德城，2024年4月1日（GLOBE NEWSWIRE）——专注于发现和开发用于治疗基因定义癌症和代谢性疾病患者的共价小分子的临床阶段生物制药公司Biomea Fusion, Inc.（纳斯达克股票代码：BMEA）（“Biomea” 或 “公司”）今天宣布，2024年4月1日，Biomea的薪酬委员会成立董事会授予两名新员工非合格股票期权，以购买总计6,500股公司普通股。每位员工的股票期权所依据的股票将在四年内按季度归属1/16，在每种情况下，视每位员工在该归属日期继续在公司工作而定。上述所有奖励都是根据Biomea的2023年激励股权计划（“计划”）发放的。
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by Biomea's board of directors on November 17, 2023.
根据纳斯达克上市规则5635（c）（4），上述每项奖励均作为激励材料发放给在公司工作的员工，并且是根据本计划的条款发放的。该计划于 2023 年 11 月 17 日由 Biomea 董事会通过。
About Biomea Fusion
关于 Bioma融合
Biomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.
Biomea Fusion是一家临床阶段的生物制药公司，专注于发现和开发口服共价小分子，以治疗代谢性疾病和基因定义的癌症患者。共价小分子是一种与其靶蛋白形成永久键的合成化合物，与传统的非共价药物相比，它具有许多潜在的优势，包括更高的靶点选择性、更低的药物暴露以及能够推动更深、更持久的反应。
We are utilizing our proprietary FUSION System to discover, design and develop a pipeline of next-generation covalent-binding small molecule medicines designed to maximize clinical benefit for patients with various cancers and metabolic diseases, including diabetes. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure.
我们正在利用我们专有的FUSION系统来发现、设计和开发下一代共价结合小分子药物产品线，旨在最大限度地提高包括糖尿病在内的各种癌症和代谢性疾病患者的临床益处。我们的目标是对我们所服务的患者的疾病治疗产生巨大影响。我们的目标是治愈。
Visit us at biomeafusion.com and follow us on LinkedIn, Twitter and Facebook.
在 biomeafusion.com 上访问我们并关注我们 领英， 推特 和 Facebook。
CONTACT: Contact: Investor Relations Chunyi Zhao, PhD Associate Director of Investor Relations & Corporate Development czhao@biomeafusion.com
联系人：联系人：投资者关系赵春义博士，投资者关系与企业发展副总监 czhao@biomeafusion.com